EXACT Therapeutics AS
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
Locally Advanced Pancreatic Adenocarcinoma
Acoustic Cluster Therapy
Modified FOLFIRINOX
PHASE2
Patients with Locally Advanced Pancreatic Cancer who have not received prior treatment to their pancreatic cancer will receive ACT treatment (the drug PS101 and ultrasound application to the tumor) with up to eight 2-week cycles of modified FOLFIRINOX chemotherapy. ACT treatment will be given on Day 1 of each cycle of chemotherapy. Patients' well-being and side effects will be assessed at the same visits. The objective efficacy of the treatment will be assessed by CT scans every 8 weeks.
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 25 participants |
| Masking : | NONE |
| Primary Purpose : | TREATMENT |
| Official Title : | A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer |
| Actual Study Start Date : | 2025-06-19 |
| Estimated Primary Completion Date : | 2026-12-15 |
| Estimated Study Completion Date : | 2027-07-15 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
HonorHealth Research Institute
Scottsdale, arizona, United States, 85258
RECRUITING
Henry Ford Centre
Detroit, road cancer, United States, 48202
RECRUITING
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
RECRUITING
Brown University Cancer Institute
Providence, Rhode Island, United States, 02906